Sun Pharma’s $11.8B Organon deal lifts pharma M&A value despite volume slump
India’s pharma and healthcare deal activity fell to a four-quarter low in Q2 2026, with volumes down 17% quarter on quarter. Total deal value reached $13.9 billion, largely due to Sun Pharmaceutical Industries’ $11.8 billion acquisition of Organon.
India’s pharma and healthcare deal volume fell to a four-quarter low in Q2 2026, but values reached $13.9 billion, led by Sun Pharma’s $11.8 billion Organon acquisition. Investment continued in specialty pharma, biotech, diagnostics, wellness and precision medicine.
Why this matters
No related recent signals were provided. Sun Pharma’s Organon acquisition stands out as the transaction that offset a broader quarterly decline in India pharma and healthcare deal activity.
Retail-company signals are accelerating, up 1,087,500% QoQ.